Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lampertz

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
British Journal of Haematology|April 1, 1996
Serum erythropoietin in chronic lymphocytic leukaemiaY Beguin, S Lampertz, D Bron, et al.
Cancer Genetics and Cytogenetics|November 7, 2000
Inv(12)(q15q24): a nonrandom change associated with myelodysplasia?G Scantamburlo, S Lampertz, C Croisiau, et al.
Leukemia|December 1, 1993
Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemiaY Beguin, S Lampertz, D De Groote, et al.
British Journal of Haematology|August 10, 2000
Deletion of the 5'-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patientsC Herens, F Tassin, V Lemaire, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
British Journal of Haematology|April 1, 1996
Serum erythropoietin in chronic lymphocytic leukaemiaY Beguin, S Lampertz, D Bron, et al.
Cancer Genetics and Cytogenetics|November 7, 2000
Inv(12)(q15q24): a nonrandom change associated with myelodysplasia?G Scantamburlo, S Lampertz, C Croisiau, et al.
Leukemia|December 1, 1993
Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemiaY Beguin, S Lampertz, D De Groote, et al.
British Journal of Haematology|August 10, 2000
Deletion of the 5'-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patientsC Herens, F Tassin, V Lemaire, et al.
Pageof 1